Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial.

ABSTRACT:

Background and purpose

The Interventional Management of Stroke (IMS) III study tested the effect of intravenous tissue-type plasminogen activator (tPA) alone when compared with intravenous tPA followed by endovascular therapy and collected cost data to assess the economic implications of the 2 therapies. This report describes the factors affecting the costs of the initial hospitalization for acute stroke subjects from the United States.

Methods

Prospective cost analysis of the US subjects was treated with intravenous tPA alone or with intravenous tPA followed by endovascular therapy in the IMS III trial. Results were compared with expected Medicare payments.

Results

The adjusted cost of a stroke admission in the study was $35 130 for subjects treated with endovascular

SUBMITTER: Simpson KN 

PROVIDER: S-EPMC4128893 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature